Syncona's portfolio includes commercial-stage companies that have products being marketed and sold in approved territories.
Autolus, which was founded by Syncona 2014, is Syncona’s second commercial stage company, with its first, Blue Earth, having been sold in 2019.
Autolus was granted approval from the FDA for its lead therapy, AUCATZYL® (obe-cel) in November 2024, and has subsequently commenced commercial launch. This novel CAR T-cell therapy has the potential to be a best-in-class therapy for patients with r/r B-ALL, supported by its very positive safety profile compared to current CD19 CAR T-cell therapies.
Portfolio in numbers
Unless stated all financials at 31 March 2025
£35m
Value in commercial portfolio
8
Number of clinical trials
1
Commercial product (AUCATZYL®)
Our commercial companies
Commercial company pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
